EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?

Gavin P Reynolds iD

Journal of Psychopharmacology · 2024

DOI: 10.1177/02698811241249415 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Psychopharmacology, 2024. Verfasst von Gavin P Reynolds. Beteiligte Einrichtung: Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK. Hauptthemen laut MEDLINE: Antipsychotic Agents, Receptors, Dopamine D2, Schizophrenia, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A major effort of the pharmaceutical industry has been to identify and market drug treatments that are effective in ameliorating the symptoms of psychotic illness but without the limitations of the current treatments acting at dopamine D2 receptors. These limitations include the induction of a range of adverse effects, the inadequate treatment response of a substantial proportion of people with schizophrenia, and the generally poor response to negative and cognitive features of the disease. Recently introduced drug treatments have gone some way to avoiding the first of these, with a reduced propensity for weight gain, cardiovascular risk and extrapyramidal motor effects. Despite claims of some small improvements in negative symptoms, these drugs have not demonstrated substantial increases in efficacy. Of the drugs currently in development as antipsychotic agents, several are misleadingly described as having novel ‘non-dopaminergic’ mechanisms that may offer improvements in addressing the limitations of adverse effects and efficacy. It will be argued, using the trace amine-associated receptor 1 agonist as an example, that several of these new drugs still act primarily through modulation of dopaminergic neurotransmission and, in not addressing the primary pathology of schizophrenia, are therefore unlikely to have the much-needed improvements in efficacy required to address the unmet need associated with resistance to current treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsReceptors, Dopamine D2SchizophreniaReceptors, G-Protein-CoupledHumansAnimalsTrace Amine-Associated Receptors

Stichwörter der Autor:innen

D2 receptorSchizophreniaantipsychotic agentsdopaminepsychosistrace amine-associated receptor 1ulotaront

Substanzen

Antipsychotic AgentsReceptors, Dopamine D2Receptors, G-Protein-CoupledTrace Amine-Associated Receptors

Autor:innen und Institutionen

  • Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
  • Rotherham Doncaster and South Humber NHS Foundation Trust, Doncaster, UK.

ORCID-Profile: Gavin P Reynolds

Zitieren

APA

Reynolds, G. P. (2024). The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241249415

Vancouver

Reynolds GP. The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?. Journal of Psychopharmacology. 2024. doi:10.1177/02698811241249415

BibTeX
@article{Reynolds2024,
  author = {Reynolds, Gavin P},
  title = {The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?},
  journal = {Journal of Psychopharmacology},
  year = {2024},
  doi = {10.1177/02698811241249415}
}
Kostenlos starten →